Bouma Bonno N, Mosnier Laurent O
Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, California 92037, USA.
Ann Med. 2006;38(6):378-88. doi: 10.1080/07853890600852898.
The thrombin-catalysed conversion of plasma fibrinogen into fibrin and the development of an insoluble fibrin clot are the final steps of the coagulation cascade during haemostasis. A delicate balance between coagulation and fibrinolysis determines the stability of the fibrin clot. Thrombin plays a central role in this process, it not only forms the clot but it is also involved in stabilizing the clot by activating thrombin activatable fibrinolysis inhibitor (TAFI). Activated TAFI protects the fibrin clot against lysis. Here we will discuss the mechanisms for regulation of fibrinolysis by thrombin. The role of the coagulation system for the generation of thrombin and for the activation of TAFI implies that defects in thrombin generation will directly affect the protection of clots against lysis. Thus, defects in activation of TAFI might contribute to the severity of bleeding disorders. Vice versa an increased activation of TAFI due to an increased rate of thrombin generation might lead to thrombotic disorders. Specific inhibitors of activated TAFI or inhibitors that interfere with the generation of thrombin might provide novel therapeutic strategies for thrombolytic therapy. Besides having a role in the regulation of fibrinolysis, TAFI may also have an important function in the regulation of inflammation, wound healing and blood pressure.
凝血酶催化血浆纤维蛋白原转化为纤维蛋白以及形成不溶性纤维蛋白凝块是止血过程中凝血级联反应的最后步骤。凝血和纤维蛋白溶解之间的微妙平衡决定了纤维蛋白凝块的稳定性。凝血酶在这一过程中起核心作用,它不仅形成凝块,还通过激活凝血酶激活的纤维蛋白溶解抑制剂(TAFI)参与凝块的稳定。活化的TAFI保护纤维蛋白凝块不被溶解。在此,我们将讨论凝血酶调节纤维蛋白溶解的机制。凝血系统在凝血酶生成和TAFI激活中的作用意味着凝血酶生成缺陷将直接影响凝块对溶解的保护。因此,TAFI激活缺陷可能导致出血性疾病的严重程度增加。反之,由于凝血酶生成速率增加导致TAFI激活增加可能会导致血栓形成性疾病。活化TAFI的特异性抑制剂或干扰凝血酶生成的抑制剂可能为溶栓治疗提供新的治疗策略。除了在纤维蛋白溶解调节中起作用外,TAFI在炎症、伤口愈合和血压调节中可能也具有重要功能。